Tissue Acquisition for Molecular Diagnostics

• Sponsor: National Cancer Institute (NCI) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00001580
• Collaborator: (none)
• Enrollment: 50
• Location: 1
• Duration (Months): 69
• Patients Per Site Per Month: 0.7

Study Details

Study Description

Brief Summary

Acquisition of fresh tumor and normal tissue samples are necessary for the preparation of cDNA libraries, microarray chips, and tissue specific probes, and proteomics development and validation. This protocol will allow acquisition of samples at the time of tissue sampling for surgery, diagnostic tests, or therapeutic phereses. These samples will be forwarded without patient identifiers, pathology reports, or other labels. Tissue pathology will be verified within the Laboratory of Pathology and samples used strictly for CGAP and Proteomic Initiative indications.

Condition or Disease	Intervention/Treatment	Phase
Neoplasm

Detailed Description

Acquisition of fresh tumor and normal tissue samples is necessary for the preparation of cDNA libraries, microarray chips, tissue specific probes, and proteomics development and validation. This protocol will allow acquisition of patient samples at the time of tissue sampling for surgery, diagnostic tests, or therapeutic phereses. These samples will be forwarded without patient identifiers, pathology reports, or other labels. Tissue pathology will be verified within the Laboratory of Pathology and samples used strictly for CGAP and Proteomic Initiative indications.

Study Design

• Study Type: Observational
• Official Title: Tissue Acquisition for Molecular Diagnostics
• Study Start Date: Jun 1, 1997
• Study Completion Date: Mar 1, 2003

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

INCLUSION CRITERIA:

All patients willing to sign the informed consent for whom tissue, blood or body fluids will be available are eligible.

Histopathologic diagnosis will be confirmed in the Laboratory of Pathology, National Cancer Institute and is not a criteria for inclusion.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Cancer Institute (NCI)	Bethesda	Maryland	United States	20892

Sponsors and Collaborators

• National Cancer Institute (NCI)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

• Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA. Laser capture microdissection. Science. 1996 Nov 8;274(5289):998-1001.
• Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 1995 Jul 15;55(14):2959-62.
• Krizman DB, Chuaqui RF, Meltzer PS, Trent JM, Duray PH, Linehan WM, Liotta LA, Emmert-Buck MR. Construction of a representative cDNA library from prostatic intraepithelial neoplasia. Cancer Res. 1996 Dec 1;56(23):5380-3.

• ClinicalTrials.gov Identifier: NCT00001580
• Other Study ID Numbers: 970138; 97-C-0138
• First Posted: Nov 4, 1999
• Last Update Posted: Mar 4, 2008
• Last Verified: Mar 1, 2003

• Keywords provided by , ,: Molecular Diagnostics; Ovary; Tissue Acquisition; cDNA Library; CGAP

Study Results

No Results Posted as of Mar 4, 2008